Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$3.57 -4.5%	$2.51	$1.03 ▼ $4.00	$749.26M	1.44	7.84 million shs	7.34 million shs
CMPS COMPASS Pathways	$4.33 -0.9%	$4.01	$2.25 ▼ $8.54	$408.87M	2.12	2.47 million shs	1.07 million shs
MNMD Mind Medicine (MindMed)	$9.76 +0.4%	$7.63	$4.70 ▼ $10.44	$734.38M	2.45	1.23 million shs	1.22 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	-4.55%	+10.53%	+62.27%	+144.52%	+136.42%
CMPS COMPASS Pathways	-0.92%	+0.70%	+56.88%	+13.35%	-37.61%
MNMD Mind Medicine (MindMed)	+0.41%	+9.91%	+42.69%	+56.66%	+11.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	3.321 of 5 stars	3.8	4.0	2.9	1.7	0.6
CMPS COMPASS Pathways	1.7483 of 5 stars	3.4	1.0	2.3	0.8	0.6
MNMD Mind Medicine (MindMed)	1.9789 of 5 stars	3.6	1.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.50	Strong Buy	$9.00	152.10% Upside
CMPS COMPASS Pathways	2.86	Moderate Buy	$17.00	292.61% Upside
MNMD Mind Medicine (MindMed)	3.22	Buy	$24.00	145.90% Upside

Current Analyst Ratings Breakdown

Latest ATAI, MNMD, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/2/2025	ATAI atai Life Sciences	Aegis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
6/23/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/23/2025	CMPS COMPASS Pathways	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ In-Line	$11.00 ➝ $6.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	MNMD Mind Medicine (MindMed)	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	2,307.14	N/A	N/A	$0.69 per share	5.17
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$3.21 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/31/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$108.68M	-$1.29	N/A	N/A	N/A	N/A	-40.33%	-32.13%	7/31/2025 (Estimated)

Latest ATAI, MNMD, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATAI atai Life Sciences	-$0.13	N/A	N/A	N/A	N/A	N/A
7/31/2025	Q2 2025	CMPS COMPASS Pathways	-$0.41	N/A	N/A	N/A	N/A	N/A
7/31/2025	Q2 2025	MNMD Mind Medicine (MindMed)	-$0.37	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
CMPS COMPASS Pathways	0.11	10.18	10.18
MNMD Mind Medicine (MindMed)	0.10	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
CMPS COMPASS Pathways	46.19%
MNMD Mind Medicine (MindMed)	27.91%

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
CMPS COMPASS Pathways	3.93%
MNMD Mind Medicine (MindMed)	2.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
MNMD Mind Medicine (MindMed)	40	75.55 million	73.70 million	Optionable

ATAI, MNMD, and CMPS Headlines

Recent News About These Companies

Mind Medicine: Heading In The Right Direction

July 24 at 8:17 AM | seekingalpha.com

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

July 24 at 7:37 AM | businesswire.com

All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy

July 22, 2025 | zacks.com

Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 11.7% - What's Next?

July 21, 2025 | marketbeat.com

MindMed Announces New Employee Inducement Grants

July 14, 2025 | businesswire.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Sold by Moloney Securities Asset Management LLC

July 12, 2025 | marketbeat.com

Capital Advisors Inc. OK Makes New Investment in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

July 8, 2025 | marketbeat.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Recommendation of "Buy" by Brokerages

July 4, 2025 | marketbeat.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Insider Sells $53,366.40 in Stock

June 27, 2025 | insidertrades.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Insider Daniel Karlin Sells 7,848 Shares

June 26, 2025 | marketbeat.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Insider Mark Sullivan Sells 11,491 Shares

June 26, 2025 | marketbeat.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) CEO Robert Barrow Sells 26,491 Shares

June 26, 2025 | marketbeat.com

MNMD Mind Medicine (MindMed) Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Why Mind Medicine Gave Investors a Powerful Buzz in May

June 4, 2025 | msn.com

Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade

June 2, 2025 | zacks.com

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 27, 2025 | finance.yahoo.com

MindMed Announces New Employee Inducement Grants

May 19, 2025 | businesswire.com

Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?

May 13, 2025 | zacks.com

Why Mind Medicine (MindMed) Inc.’s (MNMD) Stock Is Up 5.37%

May 12, 2025 | aaii.comA

Earnings call transcript: MindMed Q1 2025 results show mixed signals

May 10, 2025 | uk.investing.com

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI, MNMD, and CMPS Company Descriptions

atai Life Sciences NASDAQ:ATAI

$3.57 -0.17 (-4.55%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$3.02 -0.55 (-15.27%)

As of 07/25/2025 07:59 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

COMPASS Pathways NASDAQ:CMPS

$4.33 -0.04 (-0.92%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$4.27 -0.06 (-1.39%)

As of 07/25/2025 07:34 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Mind Medicine (MindMed) NASDAQ:MNMD

$9.76 +0.04 (+0.41%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$9.68 -0.08 (-0.82%)

As of 07/25/2025 07:59 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time